collagenase
Commercial- Indications
- Chronic dermal ulcers, Severe burns
Company intelligence / Profile preview
DFB Pharmaceuticals operates as a private healthcare investment and management group with a history of building businesses in pharmaceuticals, biotechnology, dermatology, wound care, and contract manufacturing. Its current portfolio includes clinical-stage oncology programs targeting solid tumors with reduced toxicity profiles through its subsidiary Nanology. Through its wholly owned subsidiary Phyton Biotech®, it leads in plant cell fermentation-based production of pharmaceutical ingredients like Paclitaxel and Docetaxel. The company has previously developed leading products in wound care and dermatology before divesting those businesses.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DFB Biotech.